Literatur
Brandi G, Farioli A, Astolfi A, Biasco G, Tavolari S (2015) Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies. Oncotarget 6:14744–14753
Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, Weatherly J, Zuo M, Zinner R, Hong D, Meric-Bernstam F, Janku F, Crane CH, Mishra L, Vauthey JN, Wolff RA, Mills G, Javle M (2014) Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS ONE 9:e115383
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
H. Alakus und C. Bruns geben an, dass kein Interessenkonflikt besteht.
Rights and permissions
About this article
Cite this article
Alakus, H., Bruns, C. FGFR-Inhibition beim cholangiozellulären Karzinom. Onkologe 24, 425–426 (2018). https://doi.org/10.1007/s00761-018-0370-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00761-018-0370-7